<DOC>
	<DOCNO>NCT02865538</DOCNO>
	<brief_summary>This multi-center , double-blind , randomize , placebo-controlled multiple ascend dose study post-menopausal woman vasomotor symptom . Single ascend dos NT-814 investigate 4 cohort . Each cohort comprise 20 subject . Subjects dose 14 day .</brief_summary>
	<brief_title>Evaluation Pharmacokinetics Safety NT-814 Post-Menopausal Women With Vasomotor Symptoms</brief_title>
	<detailed_description />
	<criteria>Postmenopausal female subject experience frequent moderate severe hot flash . Menopause define : 12 month spontaneous amenorrhea ; OR least 6 week ' postsurgical bilateral oophorectomy without hysterectomy . Key BMI &gt; 35kg/m2 . Any active comorbid disease , ECG laboratory result deem investigator clinically significant could impact safety study conduct could interfere study evaluation , procedures completion . Use prohibit medication define protocol . Inability unwillingness comply study procedures requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hot flash</keyword>
	<keyword>Post-menopausal</keyword>
</DOC>